SCHEMBL2370701

SCHEMBL2370701

CC(C)(C)COc1cc2c(=O)c3cc(Br)ccc3oc2c(F)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 13/20 0.38
PIM1 P11309 12/20 0.38
CDC7 O00311 4/20 0.38
CSNK2A1 P68400 4/20 0.38
CSNK2A2 P19784 11/20 0.38
PIM3 Q86V86 10/20 0.38
PIM2 Q9P1W9 10/20 0.38
CSNK2A3 Q8NEV1 1/20 0.38
HSD17B10 Q99714 1/20 0.37
KMT2A Q03164 1/20 0.37
TBK1 Q9UHD2 1/20 0.36
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
ATM Q13315 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1995244 0.75 KDM4E (0.51) PIM1KMT2ACA12CA9ATM
SCHEMBL571166 0.75 PIM1 (0.45) CSNK2BPIM1CDC7CSNK2A1CSNK2A2
SCHEMBL2371235 0.68 PIM1 (0.41) CSNK2BPIM1CDC7CSNK2A1CSNK2A2
SCHEMBL19513555 0.67 GABRP (0.42) CSNK2BPIM1CDC7CSNK2A1CSNK2A2
SCHEMBL2370587 0.67 MAPT (0.54) CSNK2BCSNK2A2HSD17B10KMT2ACA12
SCHEMBL2371483 0.67 NPC1 (0.46) CSNK2BPIM1CDC7CSNK2A1CSNK2A2
SCHEMBL2588529 0.66 PIM1 (0.58) CSNK2BPIM1CDC7CSNK2A1CSNK2A2
SCHEMBL29416622 0.66 PIM1 (0.58) CSNK2BPIM1CDC7CSNK2A1CSNK2A2
SCHEMBL12213465 0.65 KMT2A (0.46) CSNK2BPIM1CDC7CSNK2A1CSNK2A2
SCHEMBL2370938 0.65 NUDT1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012446-B2 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2015-04-21 US disclosed
US-20140045828-A1 AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. 2014-02-13 US disclosed
EP-2547686-B1 AMINO-DIHYDROOXAZINE AND AMINO-DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA-SECRETASE MODULATORS AND THEIR MEDICAL USE AMGEN INC (US) 2014-01-22 EP disclosed
US-8497264-B2 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2013-07-30 US disclosed
EP-2547686-A1 AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251186-A1 Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115928-A1 AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045828-A1 AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, APP, BACE2 CSNK2B 532/4885PIM1 3762/4885CDC7 3067/4885
US-20110251186-A1 Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use BACE1, APP, BACE2 CSNK2B 532/4885PIM1 3762/4885CDC7 3067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.